myelodysplastic neoplasms

Decoding Bone Marrow Architecture: A New Biomarker for Disease Activity and Treatment Response in Myelodysplastic Neoplasms

By MedXY 08/17/2026

Spatial remodeling of bone marrow in myelodysplastic neoplasms (MDS) reveals distinctive tissue-state signatures that better capture disease activity and predict therapeutic response beyond traditional blast counts.

Hematology-Oncology Internal Medicine news

Unraveling the FOLR2-IRF2BP2 Axis: How Excess Folic Acid Impairs Erythropoiesis in Myelodysplastic Neoplasms

By MedXY 08/11/2026

Excess folic acid promotes erythropoiesis impairment in myelodysplastic neoplasms via the FOLR2-IRF2BP2 axis, revealing potential therapeutic targets involving dietary folic acid restriction and pathway inhibition.

Hematology-Oncology news Oncology

Frontline Allogeneic Transplantation Outperforms Pretransplant IPSS-M Downstaging in Myelodysplastic Neoplasms

By MedXY 05/21/2026

In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mortality.